AI-assisted, source-referenced information. Independent clinical review is pending. Our standards.
The short answer

Wegovy's adverse effects need to be interpreted alongside dose, timing and other medicines. Keep the specific formulation and strength clear, especially when discussing the newer higher-dose option.

Give digestive symptoms a clear timeline

Nausea, vomiting, diarrhoea and constipation are recognised with semaglutide. Record whether a symptom began before treatment, after an injection or after an increase. Note its duration and effect on meals, fluids, sleep and work. This gives the clinician information that a simple severity score cannot fully capture.

Do not advance to the next strength while avoiding a discussion of substantial symptoms. The product information allows the prescriber to reconsider escalation when gastrointestinal effects are significant. A repeat order should follow that decision rather than committing you to a strength before your symptoms are assessed.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics

Constipation needs more than a day count

Tell the pharmacist what is normal for you, when the pattern changed, whether stools are hard and whether pain or bloating is present. Mention reduced food or fluid intake and any other medicine changes. NHS advice supports seeking help when constipation persists or is accompanied by concerning features.

Ask for a suitable plan before repeatedly adding over-the-counter remedies. Severe pain, vomiting or marked abdominal swelling should not be treated as an ordinary constipation problem without assessment. If symptoms are recurrent, agree when the plan should be reviewed rather than continuing a remedy indefinitely.

Sources: NHS: Constipation in adults; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet

Report the actual strength when describing unusual sensations

The higher-dose STEP UP trial reported altered skin sensations more often with 7.2 mg than with 2.4 mg. This evidence makes the dose relevant when someone describes unusual sensitivity, burning or discomfort. It does not establish that every new skin symptom is caused by semaglutide or that it should be ignored.

Describe where the sensation occurs, whether there is a visible rash and whether it affects daily activities. Keep a photograph if a visible change comes and goes. Seek urgent help for breathing difficulty or swelling suggesting a serious allergic reaction; those symptoms should not wait for a routine dose review.

Sources: The Lancet Diabetes & Endocrinology / PubMed: STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesity; NHS: Anaphylaxis: emergency symptoms and action

Separate common symptoms from warning signs

Severe persistent abdominal pain, particularly radiating to the back, needs urgent assessment for possible pancreatitis or another cause. Persistent vomiting with low urine output or dizziness can indicate dehydration. Sudden vision loss, especially in one eye, requires urgent eye casualty or A&E assessment under MHRA semaglutide advice.

Have the medicine name, strength and last dose date available. Mention other glucose-lowering medicines because hypoglycaemia risk and management depend on the combination. Do not drive with impaired vision, significant dizziness or symptoms of low blood sugar.

Sources: MHRA: GLP-1 medicines: strengthened warnings on acute pancreatitis; NHS: Dehydration: symptoms and when to get help; MHRA: MHRA updates semaglutide guidance on very rare NAION; NHS: Low blood sugar: hypoglycaemia

Leave the review with a usable next step

Ask whether the current symptoms change the next dose, escalation timing or need for assessment. Confirm which symptoms should trigger earlier contact and who provides that advice outside scheduled reviews. If another service assessed you urgently, send its findings to the prescriber so the ongoing decision uses the same information.

Discuss nutrition if reduced appetite has become difficulty eating. A treatment review should not define success solely as continued weight loss despite feeling unwell. Report suspected adverse effects through Yellow Card when appropriate, while keeping clinical care and safety reporting as separate tasks.

Sources: NICE: Overweight and obesity management: medicines and surgery; NHS Bath and North East Somerset, Swindon and Wiltshire ICB: GLP-1 treatment: nutritional considerations for prescribing clinicians; MHRA: GLP-1 medicines for weight loss and diabetes: what you need to know

Questions, answered.

Is every new symptom definitely caused by Wegovy?

No. Timing may help an assessment, but a clinician may need to investigate other causes. Serious symptoms require care regardless of the cause.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet

Can I compare side effects without stating the dose?

Sources & further reading

Original sources for this guide. Source checks are not independent clinical review.

  1. Wegovy FlexTouch: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  2. Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  3. Constipation in adultsNHS · Accessed 19 November 2026
  4. STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesityThe Lancet Diabetes & Endocrinology / PubMed · Accessed 19 November 2026
  5. Anaphylaxis: emergency symptoms and actionNHS · Accessed 19 November 2026
  6. GLP-1 medicines: strengthened warnings on acute pancreatitisMHRA · Accessed 19 November 2026
  7. Dehydration: symptoms and when to get helpNHS · Accessed 19 November 2026
  8. MHRA updates semaglutide guidance on very rare NAIONMHRA · Accessed 19 November 2026
  9. Low blood sugar: hypoglycaemiaNHS · Accessed 19 November 2026
  10. Overweight and obesity management: medicines and surgeryNICE · Accessed 19 November 2026
  11. GLP-1 treatment: nutritional considerations for prescribing cliniciansNHS Bath and North East Somerset, Swindon and Wiltshire ICB · Accessed 19 November 2026
  12. GLP-1 medicines for weight loss and diabetes: what you need to knowMHRA · Accessed 19 November 2026